Outcome measures following Sono and Photodynamic Therapy – A Case Series

Julian N. Kenyon1*

1The Dove Clinic, Twyford, Winchester, Hampshire, SO21 1NT, England.

ABSTRACT

Sono and Photodynamic Therapy (SPDT) is a novel therapeutic modality that utilises a non-toxic photosensitive agent with reported ultrasound-activated properties. SPDT has previously demonstrated significant tumour cell inhibition in animal studies. There has been much research into the efficacy of photodynamic therapy and development in understanding of the underlying mechanism of tumour cytotoxicity. Synergistic ultrasound activation represents a promising development to Photodynamic Therapy, as photo-activation is limited by access and penetrance issues. Ultrasound has been demonstrated to activate a number of sono-sensitive agents allowing the possibility of non-invasive targeted treatment of deeper tumour sites than is currently achievable with photodynamic therapy. This case series of 17 consecutive patients with a variety of cancer diagnoses outlines clinical outcomes over a four-year period of SPDT. The results have been encouraging in that all cases who carried our Circulating Tumour Cell Tests before and after SPDT showed a significant drop in tumour cells post-SPDT. SPDT is worthy of further investigation as an effective and well tolerated treatment for a wide variety of primary and metastatic tumours, including those refractory to Chemotherapy.

Introduction

A case series of 17 consecutive patients with a variety of Cancer diagnoses outlines clinical outcomes over a four-year period of Sono and Photodynamic Therapy (SPDT).

This is a novel therapeutic modality that utilises a nontoxic photosensitive agent with reported ultrasound-activated properties. This treatment centres around the development of a specific light and ultrasound activated sensitiser (Sonnelux1) which has previously demonstrated tumour cell inhibition in animal studies and provides a new method of inducing targeted tumour cell necrosis. Many of the patients included in this case series have advanced metastatic cancer diagnoses, and most have failed to respond to conventional management approaches. We have previously published in this area1-2 Many of these cases showed significant extension of predicted median survival and also of outcome measures as measured by Circulating Tumour Cell Tests3. Other Authors have demonstrated significant results using SPDT4-6.

Background

Photodynamic Therapy – Light Activated Therapy

Photodynamic Therapy (PDT) is an established therapeutic option for a variety of pre-cancerous and malignant pathologies. The majority of PDT photosensitive agents possess a heterocyclic ring structure similar to that of chlorophyll
or the haem group in haemoglobin that can be administered via topical or systemic routes. The photosensitiser becomes activated by light energy applied from an LED or coherent laser emission source. Following absorption of light at a specific wavelength by the photosensitiser, a transfer and translation occurs of light energy into a chemical reaction. In the presence of molecular oxygen this produces singlet oxygen (1O2) or superoxide (O2-), and induces cell damage through direct and indirect cytotoxicity. A variety of photosensitisers demonstrates elective absorption into malignant cells, increasing the potential to target cytotoxicity and limit unwanted side-effects.

Photo-activation is however limited to surface pathology, or tumour mass capable of being targeted via endoscopic access. This is due to absorption of light into surrounding tissue, which creates limitation on penetrance and the depth of photosensitiser activation. The use of new photosensitisers sensitive to longer wavelengths of light increases depth of penetration, but effective non-invasive treatment of deep tumour sites remains problematic.

Sonodynamic Therapy – Ultrasound Activated Therapy

Ultrasound is a mechanical wave with periodic vibrations of particles in a continuous, elastic medium at frequencies equal to or greater than 20 kHz. It is not only perceived as safe, but has excellent tissue penetrating ability without major attenuation of its energy. Therefore, the potential medical application of ultrasound has been evaluated extensively and has led to the routine use of ultrasound for diagnostic imaging of soft tissue.

Ultrasound Activated therapy (sonodynamic therapy), the ultrasound dependent enhancement of cytotoxic activities of certain compounds (sonosensitisers), is an attractive modality for cancer treatment with potential to focus the ultrasound energy on tumour sites buried deep in tissues and to locally activate a preloaded sonosensitiser. The effect can be localised by focusing the ultrasound on a defined region and choosing compounds with tumour affinity, causing enhanced cytotoxicity at pathological sites with minimal damage to peripheral healthy tissue. Potentiated cytotoxicity by ultrasound was first demonstrated when mouse leukaemia L 1210 cells were exposed to continuous wave ultrasound (2 MHz, 10 W/ cm2) while suspended in nitrogen mustard solution in vitro. Mice subsequently inoculated with these cells had longer survival times than control animals that received cells exposed to the drug but not ultrasound.

Following this, the application of low-level ultrasound to a biological target was found to potentiate chemotherapeutic cell killing with adriamycin and diaziquone. In vivo, this combined drug and ultrasound treatment resulted in statistically significant reductions in tumour volume of uterine cervical squamous cell carcinoma implanted in the cheek pouch of the Syrian hamster compared to the chemotherapeutic alone. The ultrasound applied without the chemotherapeutic agent was non-cytotoxic and produced negligible temperature elevation. The photodynamic sensitisers have also been studied for ultrasound-activated properties. They have the benefit of being non-toxic unless activated and have been demonstrated to have tumour localizing properties. Hematoporphyrin, a commonly used photo-sensitiser enhanced the killing of mouse sarcoma and rat ascites 130 tumour cells exposed in vitro to ultrasound (1.92 MHz) at intensities of 1.27 and 3.18 w/cm2, from 30% and 50% to 99% to 95% respectively [16]. Possible cytotoxic mechanisms include generation of sonosensitiser-derived radicals which initiate chain peroxidation of membrane lipids via peroxy and/or alkoxy radicals, the physical destabilization of the cell membrane by the sonosensitizer thereby rendering the cell more susceptible to shear forces and cavitation effects or ultrasound enhanced drug transport across the cell membrane (sonoporation).

Sonnelux-1 – A Dual Activation Agent

Light and Ultrasound Activation Sonnelux-1 is a metallochlorin complex, containing a highly purified mixture of several chlorophyllins, each with a different side chain and an average molecular weight of 942. Sonnelux-1 has photo-activation properties and has also been demonstrated to be extremely sensitive to ultrasound. Safety studies, including LC50 studies of Sonnelux-1 as determined in zebrafish, reveal that Sonnelux-1 is essentially non-toxic. No zebrafish death is noted at the maximum soluble concentration of the sonosensitiser (data pending publication). Sonnelux-1 is registered as non-hazardous according to OSHA standards and EU directives.
Sonnelux-1 Animal Studies Demonstrating Dose Dependent Ultrasound Activated Tumour Cytotoxicity

Sonnelux-1 has demonstrated significant tumour cell cytotoxicity following ultrasound-activation using a mouse S-180 Sarcoma model20. Following treatment, tumour volume was monitored. Significant tumour growth inhibition was seen in the group that was administered both ultrasound and Sonnelux-1 with significant (p<0.01) reduction in mean tumour we might (see Fig. 2). No significant difference occurred with ultrasound or Sonnelux administration alone.

Significantly, cytotoxicity increased in a dose-dependent manner from 0.3W/cm² to 1.2W/cm² (see Fig. 3 and Fig. 4). Histology showed coagulated necrosis or metamorphic tissue which started within 2 hours of ultrasound activation20. Tumour cytotoxicity was also reported when a bone barrier was placed between the ultrasound exposure source and the animals under study20. Studies have previously supported propagation of ultrasound through bone structure21, and this provides further support for the possibility that sufficient ultrasound activation can be achieved for tumour sites distant or within bone structure.

Method

SPDT Protocol

Sonnelux-1 is administered slowly over 2 to 5 hours sublingually to provide sustained low plasma concentration. Our regulators asked us 15 years ago to use sublingual administration, we found this to be entirely satisfactory and have not had to move on to intravenous administration. Forty-eight hours after sublingual administration the patient is exposed to a light bed containing 48 panels of LEDs emitting a combination of visible and infra-red light at the frequencies 660nm and 940nm (+/- 30nm). No photosensitivity from normal ambient light, artificial or natural has been noted but as a precaution, patients are advised not to stay in direct sunlight for periods over half an hour for one week following Sonnelux-1 administration. Light bed exposure time varies with shorter exposure duration in cases with larger tumour load. Ultrasound is then applied at 1W/cm² and a frequency of 1MHz at sites of known malignant disease, with time titrated on a case by case basis. Light and ultrasound activation is repeated on three consecutive days, and the same process of Sonnelux-1 administration followed by light and ultrasound exposure.
is repeated after one week to complete a treatment cycle. Ozone Autohaemotherapy is administered immediately before light bed exposure, aiming to increase P02 at the tumour site. Clinically, this has been observed to significantly increase the tumour cytotoxic effect of SPDT. A course of oral Dexamethasone is administered to patients dependent on tumour type, background physical status and total tumour volume. Alongside SPDT protocol, patients underwent supportive nutritional supplementation determined on a case by case basis.

**Data Collection**

Details were collated of 17 consecutive patients who received SPDT including hospital diagnosis. All of the patients except one had a Circulating Tumour Cell Test before SPDT and one after. Results have been tabulated for comparison. (Table 1)

Every patient signed an Informed Consent allowing us to use their dated in an anonymous way as we are doing in this publication.

<table>
<thead>
<tr>
<th>DOB</th>
<th>Type</th>
<th>Diagnosed</th>
<th>Clinical Outcomes</th>
<th>RGCC Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 05/04/1952</td>
<td>Abdominal Carcinosarcoma</td>
<td>January 2016</td>
<td>Debunking, followed by Colostomy. Patient refused Chemotherapy. We carried out SPDT in March 2016. Expected survival at the time I saw her on 24 February 2016 – her expected survival was one year – at the time of writing she is alive and well with no detectable tumour.</td>
<td>This patient chose not to have a Circulating Tumour Cell Test</td>
</tr>
<tr>
<td>2 24/10/1951</td>
<td>Pancreatic Cancer</td>
<td>We first saw him on 21st July 2019 with Pancreatic Cancer. He had SPDT in September 2019. The second course in May 2020. Expected survival - 1 year. He is currently alive and well.</td>
<td>13/08/2019 – 3.4 cells per 7.5ml 18/03/2020 – 3.2 cells per 7.5ml 22/09/2020 – 3 cells per 7.5ml</td>
<td></td>
</tr>
<tr>
<td>3 25/11/1958</td>
<td>Metastatic Colorectal</td>
<td>We saw him 16 July 2018 – expected survival one year. We carried out SPDT in August 2018. The patient died in December 2020.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4 05/08/1972</td>
<td>Head and Neck Squamous Cell Carcinoma.</td>
<td>We saw the patient on 23/01/2019. He refused all standard treatments, expected survival was one year. He is still alive.</td>
<td>Circulating tumour cell test carried out pre SPDT on 07/02/2019 was 5.6 cells per 7.5ml. He had SPDT and the circulating tumour cells on 21/05/2019 were 5.1 cells per 7.5ml.</td>
<td></td>
</tr>
<tr>
<td>5 20/05/1951</td>
<td>Metastatic Colorectal Cancer.</td>
<td>We saw him in November 2017 with metastatic colorectal cancer. He is alive and well with no evidence of disease. Expected survival was one year.</td>
<td>Circulating tumour cell test carried out on 09/05/2019 was 3 cells per 7.5ml. He had SPDT and the circulating tumour cell test on 23/10/2019 was 2.2 cells per 7.5ml.</td>
<td></td>
</tr>
<tr>
<td>6 19/12/1954</td>
<td>Metastatic Breast Cancer</td>
<td>We first saw her on 19/05/2014 with metastatic breast cancer. Expected survival was one year.</td>
<td>Her circulating tumour cells prior to SPDT were 10.6 cells per 7.5ml. Post SPDT they were 7.3 cells per 7.5ml. She had another round of SPDT in 2016 and her circulating tumour cells before the SPDT were 5 cells per 7.5ml. Post SPDT her circulating tumour cells were 2.5 cells per 7.5ml.</td>
<td></td>
</tr>
<tr>
<td>No.</td>
<td>Date</td>
<td>Diagnosis</td>
<td>Details</td>
<td></td>
</tr>
<tr>
<td>-----</td>
<td>------------</td>
<td>----------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>23/03/1950</td>
<td>Merkel Cell Cancer on the Right Cheek</td>
<td>She had SPDT in 2019. Expected survival not known.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>She had SPDT in 2019 and her circulating tumour cells pre SPDT were 3.4 cell per 7.5ml. Post SPDT the circulating tumour cells were 2.6 cells per 7.5ml.</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>18/04/1948</td>
<td>Gleason 8 Prostate Cancer</td>
<td>His first round of SPDT was in 2017. He had another round of SPDT in March 2020.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>His circulating tumour cells were 4.4 cells prior to the SPDT in 2017. Post SPDT they were 2.4. Level was 4.4 in February 2020. Post SPDT the circulating tumour cells were down to 3.3 cells per 7.5ml.</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>18/11/1945</td>
<td>Gleason 9 Prostate Cancer</td>
<td>We saw this patient with Gleason 8 Prostate Cancer. He refused all standard treatment. We treated him with SPDT in 2017. Expected survival not known. Currently he has stable disease.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>His circulating tumour cells prior to SPDT were 4.7 cells per 7.5ml. Post SPDT the numbers had come down to 2.4 cells per 7.5ml. Then he had another course of SPDT following that course of SPDT the circulating tumour cells came down to 3.2 cells per 7.5ml.</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>19/06/1956</td>
<td>Breast Cancer</td>
<td>She had had standard treatments. We carried out SPDT in 2019. Expected survival not known. She is currently well with no complaints.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Her circulating tumour cells before SPDT were 3.5 cells per 7.5ml. Post SPDT they were 2.5 cells per 7.5ml.</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>22/02/1965</td>
<td>Metastatic Endometrial Clear Cell Cancer</td>
<td>We saw this patient with a Metastatic Endometrial Clear Cell Cancer which was chemoresistant. Expected survival was one year. We carried out SPDT in 2020 when we first saw her, her disease was progressive. She remains alive.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Her circulating tumour cells before SPDT were 6.1 cells per 7.5ml. Post SPDT the circulating tumour cells were 5.9 cells per 7.5ml.</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>22/12/1936</td>
<td>Metastatic Colorectal Cancer</td>
<td>We saw him in July 2020. He has Metastatic Colorectal Cancer. He had a hemicolecctiony and was offered chemotherapy which he turned down. We carried out SPDT in September. Expected survival was one year. He remains clinically well.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>His circulating tumour cells pre SPDT were 6 cells per 7.5ml. Post SPDT his circulating tumour cells were 3.1 cells per 7.5ml.</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>22/03/1970</td>
<td>Clear Cell Endometrial Carcinoma</td>
<td>This patient had a chemoresistant Clear Cell Endometrial Carcinoma. We carried out SPDT on her in 2016. She also has a diagnosis of Lynch Syndrome. Expected survival was two years. She is currently clear of any scan evidence of cancer.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Her circulating tumour cells pre SPDT were 7.4 cells per 7.5ml. Post SPDT they had gone down to 4.1 cells per 7.5ml.</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>29/05/1964</td>
<td>GIST Tumour</td>
<td>This patient presented to us with a GIST Tumour in March 2019. He turned down chemotherapy. This patient has been lost to follow up.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>His pre SPDT circulating tumour cell test showed 6.2 cells per 7.5ml. Following SPDT this went down to 5.8 cells per 7.5ml.</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>23/06/1967</td>
<td>Breast Cancer</td>
<td>This patient has Breast Cancer. Expected survival unknown. This patient is alive and well at the time of writing.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Her pre SPDT circulating tumour cell test was 3.5 cells per 7.5ml. Following SPDT her number of circulating tumour cells was 2.6 cells per 7.5ml.</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>07/02/1954</td>
<td>Metastatic Breast Cancer</td>
<td>This patient turned down chemotherapy and radiotherapy, we carried out SPDT. This patient has been lost to follow up.</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Her circulating tumour cell test before SPDT were 8.1 cells per 7.5ml. Post SPDT they went down to 5.6 cells per 7.5ml.</td>
<td></td>
</tr>
</tbody>
</table>
Results

All patient data is anonymously displayed in Table 1. Patient data has only been presented when a predicted median survival was known. Of those patients still alive, only those who have exceeded the predicted survival data are relevant, many patients however, are alive at the time of writing, therefore the survival benefit is unknown at the time of writing. All cases showed a reduction in Circulating Tumour Cells following SPDT except for Case 1, who refused the test.

PDT will destroy tumour down to 2cm, SDT will deal with deep-seated tumour. Therefore, combining the two deals with the tumour load and the distribution of the tumour in our patients. In the past we have tried using Light Bed treatment alone, this has some clinical benefit but this is maximised by adding in SDT.

Discussion

SPDT using Sonnelux has shown significant promise over a fifteen-year period as a safe and well tolerated non-invasive treatment, even in advanced metastatic cancer. Extension and median survival times are here reported, with patients of various cancer diagnosis.

Second and subsequent courses of Sono and Photodynamic Therapy may have further benefit in reducing tumour mass and inhibiting tumour cell growth without the total dose limitations of radiotherapy. There is a trend in the cases reported here, that further treatment reduced significantly on previous circulating tumour cell numbers.

It is suggested that unlike immunologically silent genotoxic damage produced by radiotherapy and chemotherapy, photooxidative cytotoxic lesions generated by Sono and Photodynamic Therapy are extra nuclear and result in a rapid cell death as it alerts the host’s innate immune system. Neutrophil mobilisation and innate immune cell activation are responsible for the development of tumour antigen-specific adaptive immune cascades that contribute to the eradication of Sono and Photodynamic Therapy treated cancers. This is further supported by in vitro studies which establish the tumour cells treated by PDT can be used for generating potent vaccines against cancers of the same origin.

Tumour hypoxia has been found to a characteristic feature in many solid tumours. It has been demonstrated the tumour hypoxia, either pre-existing or as a result of oxygen depletion during photodynamic therapy can significantly reduce the effectiveness of PDT-induced cell killing.

This study reports that when Sono and Photodynamic Therapy is combined with hyperoxygenation the hypoxic condition could be improved and the cell killing rate at various time points after Sono and Photodynamic Therapy could be significantly enhanced.

Previously, it has been shown in arteriopathic patients that Ozone Autohaemotherapy has a therapeutic potential by increasing oxygen delivery in hypoxic tissue.

Clinically, it appears that greater tumour response is Sono and Photodynamic Therapy following Ozone Autohaemotherapy. This would seem to relate to an increase on singlet oxygen levels in the tumour microenvironment.

Conclusion

The limitations of this study are that it is observational, and therefore this supports the suggestion for further studies using this particular approach. Sono and Photodynamic Therapy warrants further investigations, a non-invasive, well tolerated, clinically effective targeted cancer treatment capable of tumour cell necrosis and both superficial in deep malignant sites. All of the patients reported here showed a drop pre and post treatment with SPDT of their circulating tumour cells. This is indeed a remarkable finding.

Conflicts of Interest

There are no conflicts of interest.

References

4. Sonodynamic and Photodynamic Therapy in Advanced Breast
Carcinoma: A report of three cases. Xiahuai Wang MD, Weimim ZhangMD, Zhiyong Xu MD, Yifan Lu PhDo, Doug Mitchell PhD and Ralph W Moss PhD. Department of Oncology, Liu Hua Hospital, Guangzhou, China

5. Primary clinical use of Sonodynamic therapy (SDT) for advanced breast cancer. (External link) American Society of Clinical Oncology 2008 Breast Cancer Symposiom, TJ. Lewis PhD, X Wang MD.


